4-叔丁基-2,6-二甲氧基苯酚 | 6766-84-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 中文名称: 4-叔丁基-2,6-二甲氧基苯酚
• 英文名称: 4-(tert-butyl)-2,6-dimethoxyphenol
• 英文别名: 2,6-dimethoxy-4-t-butylphenol；2,6-Dimethoxy-4-tert-butylphenol；4-tert-butyl-2,6-dimethoxyphenol
• CAS: 6766-84-3
• 化学式: C₁₂H₁₈O₃
• 分子量: 210.273
• InChiKey: RJHWHMPKVCXJJP-UHFFFAOYSA-N

物化性质

• 沸点：
  302℃
• 密度：
  1.038
• 闪点：
  136℃

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  38.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-叔丁基-2,6-二甲氧基苯酚 在 三乙烯二胺 、 4DPAIPN 、 tert-butylammonium hexafluorophosphate(V) 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 36.0h， 生成 1-(tert-butyl)-3,5-dimethoxybenzene
  参考文献：
  名称：

  多种传统光氧化还原催化剂的电化学活化可诱导有效的光还原活性**

  摘要：

  在此，我们公开了电化学刺激从一系列结构多样的传统光催化剂中诱导出新的光催化活性。这些研究揭示了一种新型电子引发的光氧化还原催化剂，能够促进强 C(sp 2 )−N 和 C(sp 2 )−O 键的还原裂解。我们举例说明了这些深度还原但安全且温和的催化条件的合成用途。最后，我们采用电化学电流测量来进行反应进程动力学分析。该技术表明，该新系统的活性提高是催化剂稳定性增强的结果。

  DOI：

  10.1002/anie.202107169
• 作为产物：
  描述：

  4-叔丁基-2,6-二氯苯酚 在 sodium 、 碘化亚铜 作用下， 以 N-甲基乙酰胺 、 甲醇 为溶剂， 生成 4-叔丁基-2,6-二甲氧基苯酚
  参考文献：
  名称：

  Process for preparing pyrogallol

  摘要：

  白脲酚是通过以下步骤制备的：(A)将化学式为##STR1##的卤代化合物与化学式为ROM的碱金属烷氧化物反应，其中X代表Br或I，R.sup.1代表氢、长达10个碳原子的二级或三级烷基、2-5个碳原子的羧基或烷氧羰基，R.sup.2代表氢或1-4个碳原子的烷基，以替换每个X为OR；然后(B)脱烷基化每个OR和每个OR.sup.2，其中R.sup.2代表1-4个碳原子的烷基，并去除R.sup.1基团，如果R.sup.1不是氢的话。

  公开号：

  US04172960A1

文献信息

• The constitution of the dimers of 4,6-di-t-butyl-3-hydroxy-o-benzoquinone and 5-t-butyl-3-hydroxy-o-benzoquinone
  作者：N. M. Waldron

  DOI：10.1039/j39680001914

  日期：——

  Evidence is presented which shows that the yellow and white dimers of 4,6-di-t-butyl-3-hydroxy-o-benzoquinone are structures 3,4a,6,8-tetra-t-butyl-4a, 10a-dihydro-9,10a-dihydroxydibenzo-p-dioxin-1,2-dione (II) and 2,3a,5,7-tetra-t-butyl-3a,10a-dihydro-8,10a-dihydroxybenzo[b]cyclopenta[f][1,4]dioxepin-1,10-dione (IV), respectively. The suggested position of substitution of the t-butyl group in 5-t-butylpyrogallol

  提出的证据表明4，6-二叔丁基-3-羟基-邻苯醌的黄色和白色二聚体是结构3,4a，6,8-四叔丁基-4a，10a-二氢-9,10a-二羟基二苯并-对二恶英-1,2-二酮（II）和2,3a，5,7-四叔丁基-3a，10a-二氢-8,10a-二羟基苯并[ b ]环戊[分别为f ] [1,4] dioxepin-1,10-dione（IV）。已经证实了叔丁基在5-叔丁基邻苯三酚中的取代位置，从而确定了5-叔丁基-3-羟基-邻苯醌的二聚体为5,10-二叔丁基- 2,7-二羟基三环-[5,3,1,1 2,6] dodeca-4,9-二烯-3,8,11,12-四酮（XIII）。在制备5-叔丁基间苯三酚中，使用了新的反应序列以原位连接叔丁基。
• 3-(1′,1′-Dimethylbutyl)-1-deoxy-Δ8-THC and related compounds: synthesis of selective ligands for the CB2 receptor
  作者：John W. Huffman、John Liddle、Shu Yu、Mie Mie Aung、Mary E. Abood、Jenny L. Wiley、Billy R. Martin

  DOI：10.1016/s0968-0896(99)00219-9

  日期：1999.12

  and CB2 receptors were determined employing previously described procedures. Five of the 3-(1',1'-dimethylalkyl)-1-deoxy-delta8-THC analogues (2, n = 1-5) have high affinity (Ki = < 20 nM) for the CB2 receptor. Four of them (2, n = 1-4) also have little affinity for the CB1 receptor (Ki = > 295 nM). 3-(1',1'-Dimethylbutyl)-1-deoxy-delta8-THC (2, n = 2) has very high affinity for the CB2 receptor (Ki

  描述了15个1-deoxy-delta8-THC类似物的合成和药理作用，其中一些对CB2受体具有高亲和力。所述脱氧大麻素包括1-脱氧-11-羟基-δ8-THC（5），1-脱氧δ8-THC（6），1-脱氧-3-丁基-δ8-THC（7），1-脱氧-3 -hexyl-delta8-THC（8）和一系列3-（1'，1'-二甲基烷基）-1-deoxy-delta8-THC类似物（2，n = 0-4，6，7，其中n =侧链中的碳原子数-2）。还制备了脱氧萘丁酮（16）的三种衍生物（17-19）。使用前述方法确定每种化合物对CB1和CB2受体的亲和力。3-（1'，1'-二甲基烷基）-1-脱氧-delta8-THC类似物中的五个（2，n = 1-5）对CB2受体具有高亲和力（Ki = <20 nM）。其中四个（2，n = 1-4）对CB1受体的亲和力也很小（Ki => 295 nM）。3-（1'，1'-二
• A ligand-free, powerful, and practical method for methoxylation of unactivated aryl bromides by use of the CuCl/HCOOMe/MeONa/MeOH system
  作者：Ying Guo、Si-Zhe Ji、Cheng Chen、Hong-Wei Liu、Jian-Hong Zhao、Yu-Lin Zheng、Ya-Fei Ji

  DOI：10.1007/s11164-014-1917-x

  日期：2015.11

  A ligand-free, powerful, and practical method for mono and polymethoxylation of unactivated aryl bromides has been developed; CuCl was used as catalyst, HCOOMe as cocatalyst, and methanolic MeONa as both nucleophile and solvent. This eco-friendly procedure is characterized by operational simplicity, inexpensive substrates (unactivated mono to polybromoarenes), full conversion, and direct recovery of pure MeOH.

  一种无配体的强有效的方法已被开发用于非活化芳基溴化物的单甲氧基化和多甲氧基化；该反应使用CuCl作为催化剂，HCOOMe作为助催化剂，甲醇的MeONa作为亲核试剂和溶剂。这种环保的工艺具有操作简单、底物成本低（非活化单至多溴苯）、完全转化以及可直接回收纯MeOH的特点。
• Process for preparing alkoxyphenols
  申请人：Otsuka Kagaku Yakuhin Kabushiki Kaisha

  公开号：US04588835A1

  公开（公告）日：1986-05-13

  A process for preparing an alkoxyphenol represented by the formula: ##STR1## wherein R is hydrogen, alkyl having 1 to 4 carbon atoms, formyl, hydroxymethyl, alkoxymethyl, dialkoxymethyl, acetoxymethyl or diacetoxymethyl, R' is alkyl having 1 to 4 carbon atoms, and n is an integer of 1 to 5, characterized in that a phenol halide represented by the formula: ##STR2## wherein R and n are as defined above, and X is chlorine or bromine is reacted, in the presence of a copper salt serving as a catalyst and of a solvent, with a product prepared by heating, in the presence of a dehydrating agent, an alkali metal hydroxide and a compound of the formula R'OH wherein R' is as defined above.

  一种制备代表公式的烷氧基酚的方法：##STR1##其中R为氢、具有1至4个碳原子的烷基、甲酰基、羟甲基、烷氧甲基、二烷氧甲基、乙酰氧甲基或二乙酰氧甲基，R'为具有1至4个碳原子的烷基，n为1至5的整数，其特征在于，在催化剂铜盐和溶剂的存在下，将代表公式的酚卤素：##STR2##其中R和n如上定义，X为氯或溴，与在脱水剂存在下加热的碱金属氢氧化物和化合物R'OH（其中R'如上定义）制备的产物反应。
• Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors
  申请人：Hummersone Marc Geoffrey

  公开号：US20080194546A1

  公开（公告）日：2008-08-14

  There is provided a compound of formula I: wherein: one or two of X 5 , X 6 and X 8 is N, and the others are CH; R 7 is selected from halo, OR O1 , SR S1 , NR N1 R N2 , NR N7a C(═O)R C1 , NR N7b SO 2 R S2a , an optionally substituted C 5-20 heteroaryl group, or an optionally substituted C 5-20 aryl group, where R O1 and R S1 are selected from H, an optionally substituted C 5-20 aryl group, an optionally substituted C 5-20 heteroaryl group, or an optionally substituted C 1-7 alkyl group; R N1 and R N2 are independently selected from H, an optionally substituted C 1-7 alkyl group, an optionally substituted C 5-20 heteroaryl group, an optionally substituted C 5-20 aryl group or R N1 and R N2 together with the nitrogen to which they are bound form a heterocyclic ring containing between 3 and 8 ring atoms; R C1 is selected from H, an optionally substituted C 5-20 aryl group, an optionally substituted C 5-20 heteroaryl group, an optionally substituted C 1-7 alkyl group or NR N8 R N9 , where R N8 and R N9 are independently selected from H, an optionally substituted C 1-7 alkyl group, an optionally substituted C 5-20 heteroaryl group, an optionally substituted C 5-20 aryl group or R N8 and R N9 together with the nitrogen to which they are bound form a heterocyclic ring containing between 3 and 8 ring atoms; R S2a is selected from H, an optionally substituted C 5-20 aryl group, an optionally substituted C 5-20 heteroaryl group, or an optionally substituted C 1-7 alkyl group; R N7a and R N7b are selected from H and a C 1-4 alkyl group; R N3 and R N4 , together with the nitrogen to which they are bound, form a heterocyclic ring containing between 3 and 8 ring atoms; R 2 is selected from H, halo, OR O2 , SR S2b , NR N5 R N6 , an optionally substituted C 5-20 heteroaryl group, and an optionally substituted C 5-20 aryl group, wherein R O2 and R S2b are selected from H, an optionally substituted C 5-20 aryl group, an optionally substituted C 5-20 heteroaryl group, or an optionally substituted C 1-7 alkyl group; R N5 and R N6 are independently selected from H, an optionally substituted C 1-7 alkyl group, an optionally substituted C 5-20 heteroaryl group, and an optionally substituted C 5-20 aryl group, or R N5 and R N6 together with the nitrogen to which they are bound form a heterocyclic ring containing between 3 and 8 ring atoms, or a pharmaceutically acceptable salt thereof, with the proviso that when R 2 is unsubstituted morpholino. R N3 and R N4 together with the nitrogen atom to which they are attached form an unsubstituted morpholino and R 7 is unsubstituted phenyl, and X 5 is CH, then X 6 is not N and X 8 is not CH, or X 6 is not CH and X 8 is not N, and when R 2 is unsubstituted piperidinyl, R N3 and R N4 together with the nitrogen atom to which they are attached form an unsubstituted piperidinyl and R 7 is unsubstituted phenyl, and X 5 is CH, then X 6 is not CH and X is not N. There are also provided processes for the manufacture of a compound of Formula 1, and the use of a compound of Formula 1 as a medicament and in the treatment of cancer.

  提供了一种化合物，其化学式为I：其中：X5、X6和X8中的一个或两个是N，其余为CH；R7选自卤素、ORO1、SRS1、NRN1RN2、NRN7aC（═O）RC1、NRN7bSO2RS2a、可选取代的C5-20杂环芳基基团或可选取代的C5-20芳基基团，其中RO1和RS1选自H、可选取代的C5-20芳基基团、可选取代的C5-20杂环芳基基团或可选取代的C1-7烷基基团；RN1和RN2独立选自H、可选取代的C1-7烷基基团、可选取代的C5-20杂环芳基基团、可选取代的C5-20芳基基团或RN1和RN2与它们所连接的氮原子一起形成含有3至8个环原子的杂环环；RC1选自H、可选取代的C5-20芳基基团、可选取代的C5-20杂环芳基基团、可选取代的C1-7烷基基团或NRN8RN9，其中RN8和RN9独立选自H、可选取代的C1-7烷基基团、可选取代的C5-20杂环芳基基团、可选取代的C5-20芳基基团或RN8和RN9与它们所连接的氮原子一起形成含有3至8个环原子的杂环环；RS2a选自H、可选取代的C5-20芳基基团、可选取代的C5-20杂环芳基基团或可选取代的C1-7烷基基团；RN7a和RN7b选自H和C1-4烷基基团；RN3和RN4与它们所连接的氮原子一起形成含有3至8个环原子的杂环环；R2选自H、卤素、ORO2、SRS2b、NRN5RN6、可选取代的C5-20杂环芳基基团和可选取代的C5-20芳基基团，其中RO2和RS2b选自H、可选取代的C5-20芳基基团、可选取代的C5-20杂环芳基基团或可选取代的C1-7烷基基团；RN5和RN6独立选自H、可选取代的C1-7烷基基团、可选取代的C5-20杂环芳基基团和可选取代的C5-20芳基基团，或RN5和RN6与它们所连接的氮原子一起形成含有3至8个环原子的杂环环，或其药学上可接受的盐，但当R2为未取代的吗啡啶基时，RN3和RN4与它们所连接的氮原子一起形成未取代的吗啡啶基，R7为未取代的苯基，且X5为CH时，X6不是N且X8不是CH，或X6不是CH且X8不是N，当R2为未取代的哌啶基时，RN3和RN4与它们所连接的氮原子一起形成未取代的哌啶基，R7为未取代的苯基，且X5为CH时，X6不是CH且X不是N。还提供了制造化合物I的方法，以及将化合物I用作药物治疗癌症的用途。